By KELLY O'MEARA
Special to The Journal
Americans are scared. From coast to coast, young and old have stood in lines,
signed up for lotteries and even crossed national borders with the hope of
getting a shot at this year’s limited supply of the influenza vaccine.
The credit for the mass hysteria that has swept the nation in the last two
months should be given to federal health officials, who, through ongoing public
relations campaigns that easily rival those of corporate America’s top-selling
products, have successfully convinced the public that without the vaccine tens
of thousands, or worse, might die.
In fact, the Centers for Disease Control and Prevention has told the public that
influenza is the most frequent cause of death from vaccine-preventable disease
in this country and that from 1990 through 1998, an average of 36,000
flu-related pulmonary and circulatory deaths occurred each season in the United
States.
Alan Clark, a family physician in Atlanta, specializing in emergency medicine
argues that those “deaths” cannot be confirmed.
“The CDC cannot show anyone in any year where there were 36,000 actual deaths
due to influenza,” he said. “I think the vaccine is not working, and even if
they do get the right strain of virus the chances of it being helpful is maybe
60 to 80 percent in a healthy adult, less than 50 or 60 with health problems –
and I mean maybe. The only thing the vaccine is effective for is making money
for the vaccine manufacturers.”
Even CDC officials reluctantly admit the deaths are not “real” numbers, but only
estimates. CDC spokesman Von Roebuck said the CDC uses indirect modeling methods
to estimate the numbers of deaths associated with influenza, an approach that
has been used for 40 years. Using this approach, the CDC estimates that about
36,000 influenza-associated deaths occur annually in the United States, he said.
This estimate is obtained by using the models to analyze the National Center for
Health Statistics, NCHS, for underlying respiratory and circulatory deaths. The
estimated 36,000 deaths from influenza represents about 3 percent of about 1.1
million underlying respiratory and circulatory deaths that occur during the
year.
However, what the CDC fails to tell the public is that it has no idea how many
people who died from underlying respiratory and circulatory problems actually
had the influenza infection. In other words, the CDC doesn’t know if a person
who died of pneumonia also had the flu, because those statistics are not
collected. The one fact that CDC can state for certain is this: The greatest
number of influenza deaths recorded since 1979 were 3,006 in 1981.
Still, most physicians eagerly will admit that the influenza virus is nothing
to, well, sneeze at, and that history well documents the bug’s lethality.
But is the influenza scare justified? To answer that question, The Journal
decided to take a hard look at the CDC’s historical data and last year’s flu
season as a good place to start.
Recall that public health officials announced that the 2003 flu season not only
began earlier than normal but that the strain of influenza circulating in North
America did not match the strain formulated in the vaccine. Early in the
2003-2004 flu season, the CDC advised that although a vaccine had been developed
with the wrong strain of virus it, nevertheless, “may provide some protection or
lessen the symptoms,” and continued to encourage worried Americans to be
vaccinated.
However, after analyzing 2003 data this year, the CDC acknowledged that the
2003-2004 influenza vaccine had “no or low effectiveness against ILI
(influenza-like illness).” In other words, last year’s shot didn’t work.
Mark Geier, a Silver Spring physician and president of the Genetic Centers of
America along with his son, David Geier, a Maryland consultant on vaccine
issues, argue that the “no or low effectiveness” statement by the CDC is
misleading.
“What the CDC looked at in its study of the 2003-2004 season were people who
received the vaccine versus those who did not receive the vaccine and they
followed these people for weeks to months,” explained David Geier.
“What was demonstrated was that last year’s vaccine did not prevent any
influenza-like illness – it had no statistical efficacy against the influenza
infection.” “Anyone can look at the CDC data and see that there is no
statistical difference between those who received the vaccine and those who did
not,” David Geier said.
The data can be found at the CDC Web site, www.cdc.gov, under the report titled
Preliminary Assessment of the Effectiveness of the 2003-2004 Inactivated
Influenza Vaccine Colorado, Dec. 2003.
The data shows that vaccine efficacy runs from -0.14 to 0.33. “The zero means
that statistically it is not different from zero and has no efficacy,” David
Geier said. “In other words last year’s vaccine made no difference in the rate
of developing influenza-like illness,” David Geier said. “The CDC says it had
“no or low effectiveness,” but that’s just the CDC’s spin that maybe one person
was helped but they can’t find them.”
The Geiers also point to additional historical CDC data to further question not
only whether the influenza vaccine is effective in any given year, but also
raise questions about the reported 36,000 estimated deaths associated with the
influenza virus.
“What is most disturbing is that the CDC’s own data posted at the CDC’s National
Center for Health Statistics show that the influenza vaccines do not work,” adds
Mark Geier. “What we see (from the CDC data) is that in the late 1970s between
10 and 15 million doses of influenza vaccine were given to high-risk people, and
by 2001-2002 nearly 80 million doses were distributed.
Despite the enormous increase in the number of people receiving the influenza
vaccine and the CDC’s public relations campaign to sell the vaccine, there has
not been a decrease in the population rate of influenza deaths or influenza
illnesses.” In response to Mark Geier’s claim that the “vaccines do not work,”
CDC spokesman Roebuck explained that “the studies looking at trends in mortality
over time cannot address the effectiveness of the vaccination program since
influenza vaccine information is not linked to death certificates or hospital
data.
One explanation for not seeing a decline in influenza-related hospitalizations
and deaths is the aging population, particularly persons 85 years and older. In
addition, A (H3N2) viruses have predominated in more recent seasons.”
“This response is ridiculous,” countered Mark Geier. “The rules in science and
medicine are that the vaccine manufacturers have to demonstrate efficacy – now
we have to demonstrate that it isn’t efficacious. What the CDC is saying is
‘well, the data don’t show that it’s efficacious, but the numbers aren’t good
enough so we’re going to keep giving it.’ That’s not how this is supposed to
work.
They have to prove that the vaccine is working, and the CDC has no proof.”
“Furthermore,” explained Mark Geier, “the CDC reports that roughly 100 children
die from influenza each year, but the data show that there really are between
five and 15 deaths in any given year. The CDC also touts the estimated 36,000
yearly deaths due to the influenza virus. All anyone has to do is look at the
CDC’s own data to see that in reality it is maybe 1,000 deaths.”
Mark Geier is referring to the data made available by the CDC’s National Center
for Health Statistics which show, for example, the actual number of deaths due
to influenza in 1979 were 604. The highest number of deaths recorded occurred in
1981 with a total of 3,006. These data include all age groups.
“The argument by the CDC that the vaccine is stopping these deaths doesn’t hold
up because with the increase of the vaccine over the years one would expect to
see the number of deaths going down,” Dr. Geier said. “We don’t see a decrease.
There is very little, if any, trend in these numbers and the point is there
aren’t a whole lot of deaths to be prevented.”
“Given the CDC’s data,” concludes Mark Geier, “no one should be standing in a
line thinking ‘Oh God, if I get the vaccine I’m going to live and if I don’t get
the vaccine I’m going to die, because it appears that it just doesn’t make much
difference whether you get the vaccine or not.”
Kelly O’Meara is a veteran investigative reporter who holds journalistic awards
for articles in the medical field.
Is the CDC hiding flu shot alternatives?
With the sudden announcement that this year’s supply of influenza vaccine would
be cut in half, federal and local health officials zoomed into warp drive,
apparently willing to do whatever it takes to get the scarce vaccine to those
who need it most. Barbara Loe Fisher, co-founder of the National Vaccine
Information Center, a Vienna, Va., nonprofit organization dedicated to the
prevention of vaccine injuries and deaths through public education, questions
whether the CDC has done all it can to ensure that the vaccine they tout as the
miracle cure is everything they say is cracked up to be.
“There has been this cavalier attitude toward approving both safety and efficacy
in the flu vaccine, which is difficult because every year you have a new strain
for the vaccine and they don’t do any substantive clinical trials,” she says.
She says she is not surprised that the CDC studies show the vaccine has no
efficacy in young children because there isn’t any systematic way to measure
efficacy of the flu vaccine in children or adults.
“I continue to be extremely concerned with both the safety and efficacy of this
flu vaccine,” she said. “This is the first time that babies will be getting two
flu shots and they have not studied this vaccine and it will be given to
six-month-olds simultaneously with other vaccines, including DTaP, HIV, Polio,
Pneumacoccal, Hepatitis B and the flu shot. That’s eight vaccines in one day.
This is a national experiment this year on infants with giving them two doses of
the flu vaccine.
Is there a better alternative?
The CDC quietly announced guidelines for antiviral medication on their Web site
www.cdc.gov, but only after two weeks of generating panic with scare tactics.
According to the CDC’s antiviral medication guidelines, titled Influenza
Antiviral Medications 2004-2005 Interim Chemoprophylaxis and Treatment
Guidelines, four medications have been approved for use during the flu season.
They are: Amantadine (Trade Name Symmetrel) and Rimantadine (trade name
Flumadine) were approved by the Food and Drug Administration in 1966 and 1993,
respectively, for the prevention and treatment of Influenza A.
In 1999 Sanamivir (Trade Name Relenza) and Oseltamivir (Trade Name Tamiflu) were
approved for the treatment of the influenza virus, both A and B. Tamiflu,
however, produced by Roche Pharmaceuticals, is the only antiviral medication FDA
approved for both the treatment and prevention of both A and B influenza
viruses.
Dr. Mark Geier, president of Silver Spring-based Genetic Centers of America and
consultant on vaccine issues long has been aware of the benefits of the
antiviral medications available for the treatment and prevention of the
influenza infections. “There are several drugs to choose from but Tamiflu is
better than the others because it prevents influenza strains both A and B and
has few side effects,” he said. “The fact is, I would argue that this drug is so
effective that if it were widely used there would be no influenza. People don’t
have to die from influenza because this drug is and has been available for many
years. Tamiflu can be used for treatment or prevention and it is much more
effective with an upwards prevention rate of 90 percent. Furthermore, when taken
as a treatment, it significantly reduces the symptoms and shortens the days that
a person has the infection. The vaccine has never been that effective.”
The problem is that the CDC isn’t making this information widely available,
Geier notes. “Rather the (CDC) spends time and money telling people to take the
vaccine, which is marginally effective at best. People don’t have to die from
the influenza and the CDC knows that this drug is extremely effective both in
the prevention and treatment of the influenza virus.”
Despite the CDC’s claim that the agency has made the public aware of
alternatives to the vaccine, a presentation delivered at last April’s American
Medical Association meeting by Glen Nowak, then the Associate Director for
Communications for the National Immunization Program, paints a different
picture. Nowak’s presentation includes a “Seven-Step Recipe for Generating
Interest in, and Demand for, Flu (Any other) Vaccination.”
Within the “Seven-Step Recipe,” Nowak explains that the recipe that fosters
influenza vaccine interest and demand is “medical experts and public health
authorities who publicly state concern and alarm and urge influenza
vaccination.”
Nowak further states that when health officials ring the alarm, there will be
significant media interest and attention at which time officials must frame the
flu season in terms that motivate behavior, such as characterizing it as “very
severe,” or “more severe than last or past years,” and even “deadly.”
When questioned about the Recipe, Nowak, now the Acting Director of Media
Relations for the CDC, said he was asked to find out why there was so much
late-season demand for flu vaccine in the 2003-2004 season.
“One of the things that happened in the past is that demand tends to decrease
around Thanksgiving,” he said. “What happened last year was that, going into the
first weeks of Decembe,r there was a lot of consumer demand and as part of the
presentation, I looked at what was different.”
He said several factors led to consumer demand for influenza vaccination that
were beyond the control of medical providers. “Last year the influenza arrived
early during the time when people could get vaccinated,” he noted. “And last
year the initial cases were among people who are not typically associated with
severe complications of influenza, and it tended to get more media attention.”
Nowak did not make clear in his presentation just who was responsible for the
scare tactics, but given that all but 4 million doses of last year’s ineffective
vaccine were sold, the alarm and dire outcomes certainly appeared to have
worked.
But why did they keep pushing the alarm button when the CDC knew from its own
studies that the 2003-2004 vaccine had no or low effectiveness? Nowak failed to
make note of it in his April presentation of the Seven-Step Recipe. In addition,
there is not a single mention of the antiviral medications in the Seven-Step
Recipe.
Nowak brushed off the failure to include or conduct any presentation on
antiviral medications by insisting that topic was never meant to be part of a
public seminar.
While the CDC has no immediate plans to launch a major information campaign
about the antiviral medications, Nowak claimed that the CDCs efforts about the
antiviral medications have been targeted toward our clinicians, health care
providers and healthcare professionals to make them more aware of how antivirals
can be used in treating influenza.
The concerns the CDC has about the antivirals is that “they are prescription
medications and so patients have to talk with their doctors and the antivirals
can be relatively expensive and many health plans don’t cover the cost of
antivirals,” he said.
In other words, the CDC decided not to heavily promote antiviral drugs because
they deemed them too expensive for the consumer – even though many physicians
advocate such drugs are more effective and safer than the influenza vaccine.
Instead, the CDC continues to push the influenza shot upon 4 million children
even though its own statistics indicate less than 15 children die from influenza
each year. In fact, less than 2,000 people die from the flu each year and most
of those are 85 years and older. How many of them might be alive today if they
knew about antivirals? If federal health officials are truly guardians of the
public health, wouldn’t they be aggressively promoting these drugs or have they
become salesmen for vaccine manufacturers.
CDC Pushes Fear over Reassurance
Atlanta-based family physician Alan Clark has heard patients tell him one too
many times: “Every time I get a flu shot I get sick. ’That’s not surprising, he
said, considering thimerosal (mercury) is used as a preservative in the
influenza vaccine, which knocks out the immune system.
“Many people come down with the first virus or bacteria that invades their
system,” he said. “There are better ways to prevent and treat the flu, which
brings up the idea of prescription medications that the CDC is aware of and,
more importantly, why aren’t these known to the public?”
In fact, for years public health officials have been aware of the Food and Drug
Administration approved antiviral drugs for the prevention and treatment of the
influenza virus, but still it took nearly two weeks into this year’s vaccine
shortage hysteria before the antiviral drugs were quietly recommended by
officials tasked with protecting the public health.
When The Journal asked why the CDC wasn’t pushing the antiviral medications, CDC
spokeswoman Christine Pearson insisted public health officials had made the
information available and blamed the media for dropping the ball.
“I believe, Dr. (CDC Director Julie) Gerberding has mentioned (antivirals) in
nearly all the press conferences she’s had in the last few weeks,” Pearson said.
She further insisted, “I know that it has been talked about by either Dr.
Gerberding or Secretary Thompson (Department of Health and Human Services) in
many of the press conferences that have happened. I don’t know why the media was
just interested in the supply (vaccine) issue. I can’t speculate on why the
media does what it does.”
And, in an effort to better clarify the CDC’s position on making the public
aware of the use of antiviral medications, CDC spokesman Von Roebuck explained
that it is not fair to say something is “pushed” by the CDC.
“The CDC makes recommendations based on scientific research and consultation.
Those recommendations often become the standard practice by clinicians and state
health departments,” he said.
While it may be true that the media appears to be fixated on this year’s vaccine
shortage, the missed opportunities to explore prevention and treatment
alternatives surely can be traced to the lack of interest in, and information
provided by public health officials about the antiviral drugs.
In fact, none of the information handed out by both Montgomery and Prince
George’s County officials to schools and the media contained information about
antiviral medications.
Furthermore, a review of press releases and briefings by public health officials
clearly demonstrate that information about antiviral drug use for prevention and
treatment of influenza has taken a backseat to the vaccine.
For example, on Oct. 5 public health officials announced the contamination of
half of the expected influenza vaccine but, it wasn’t until one full week later,
on Oct. 12, that Gerberding mentioned in a press briefing that they have a
stockpile of Tamiflu, which is one drug used to treat influenza or to prevent
it, and she noted, “we are in the process of purchasing a second drug,
Rimantadine, to also have in the stockpile. We are hoping to purchase up to five
million treatment courses of that drug.”
Then, on Oct. 15, 10 days after first notice of the vaccine shortage, a CDC
press release advised that pharmaceutical giant Aventis Pasteur will provide an
additional 2 million doses of the vaccine, but Gerberding makes no mention about
the antiviral drugs.
Rather than taking the opportunity to aggressively reassure the public that
there are antiviral prevention and treatment alternatives available, Gerberding
again raises the vaccine shortage fear factor and explains “this shortage is
frightening to people and they’re rushing out and standing in long lines
thinking they need the vaccine right now before it s all gone. We want them to
know that more is coming, so as hard as it may be, please try and be patient and
check with your provider ahead of time for availability of vaccine in your
area.”
On Oct. 18, two weeks into the vaccine shortage saga, the CDC posted on its web
site “Guidelines and Recommendations for Influenza Antiviral Medications”. And
the following day, Oct. 19, Health and Human Services Secretary Tommy Thompson
in a press release announced the availability of “antiviral medicines to help
keep you safe from the flu.”
If CDC spokeswoman Pearson is correct and public health officials have
communicated often about the benefits of antiviral drugs for the treatment and
prevention of influenza, why does the latest Oct. 22 CDC Public Health
Announcement focus on the limited supply of vaccine and omit any mention of
antiviral medications?
Gerberding declined requests to be interviewed.
Despite the brief and sporadic mentions by public health officials about the
availability of antiviral drugs and, in light of both the shortage of the
vaccine and the questions surrounding its efficacy, the benefits of these FDA
approved alternatives to the influenza vaccine physicians state cannot be
overstated.
There are four antiviral medication alternatives to the influenza vaccine,
including one that, unlike the vaccine, will prevent and treat any strain of
Influenza virus A or B.
Public knowledge of this medication could have been especially helpful during
last year’s flu season when the influenza vaccine did not match the circulating
virus and CDC officials admitted that the vaccine actually had “no or low
effectiveness.”
Kelly O’Meara is a veteran investigative reporter who holds journalistic awards
for articles in the medical field.